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Abstract
Background. This article summarizes the 2012 European Renal Association—European Dialysis and
Transplant Association Registry Annual Report (available at www.era-edta-reg.org) with a speciﬁc
focus on older patients (deﬁned as ≥65 years).
Methods. Data provided by 45 national or regional renal registries in 30 countries in Europe and
bordering the Mediterranean Sea were used. Individual patient level data were received from 31
renal registries, whereas 14 renal registries contributed data in an aggregated form. The incidence,
prevalence and survival probabilities of patients with end-stage renal disease (ESRD) receiving
renal replacement therapy (RRT) and renal transplantation rates for 2012 are presented.
Results. In 2012, the overall unadjusted incidence rate of patients with ESRD receiving RRT was
109.6 per million population (pmp) (n = 69 035), ranging from 219.9 pmp in Portugal to 24.2 pmp in
Montenegro. The proportion of incident patients ≥75 years varied from 15 to 44% between coun-
tries. The overall unadjusted prevalence on 31 December 2012 was 716.7 pmp (n = 451 270),
ranging from 1670.2 pmp in Portugal to 146.7 pmp in the Ukraine. The proportion of prevalent pa-
tients ≥75 years varied from 11 to 32% between countries. The overall renal transplantation rate in
2012 was 28.3 pmp (n = 15 673), with the highest rate seen in the Spanish region of Catalonia. The
proportion of patients ≥65 years receiving a transplant ranged from 0 to 35%. Five-year adjusted
survival for all RRT patients was 59.7% (95% conﬁdence interval, CI: 59.3–60.0) which fell to 39.3%
(95% CI: 38.7–39.9) in patients 65–74 years and 21.3% (95% CI: 20.8–21.9) in patients ≥75 years.
Keywords: end-stage renal disease; incidence; prevalence; renal replacement therapy; survival
Introduction
The European Renal Association—European Dialysis and
Transplant Association (ERA-EDTA) Registry annually collects
data on renal replacement therapy (RRT) for end-stage
renal disease (ESRD) from national and regional renal regis-
tries in Europe and those bordering the Mediterranean Sea.
In this article, we provide a summary of the 2012 ERA-EDTA
Registry Annual Report (available at www.era-edta-reg.org)
on the incidence and prevalence of ESRD patients receiving
RRT, on kidney transplant rates and on patient and graft sur-
vival. As the older patient (deﬁned in this article as 65 years
and over and presented in two age groups, i.e. 65–74 years,
and 75 years and over) now represents 42% of the RRT
population within Europe, this article will pay particular
attention to this patient group.
Materials and methods
In 2014, the ERA-EDTA Registry received the 2012 data
from the national and regional renal registries in 30 coun-
tries in Europe and those bordering the Mediterranean
Sea (Figure 1A). Data sets with individual patient data
were received from 31 national or regional renal registries
in 17 countries, whereas 14 national renal registries con-
tributed data in an aggregated form. The percentage
coverage of the general population by the renal registries
was >98% for all participating countries with the excep-
tion of Romania (96%), Latvia (85%) and Georgia (63.5%).
The total coverage of the European population by the ERA-
EDTA Registry in 2012 was 71.3%. A list of the European
countries with available data and those without is provided
in Appendix 1.
The RRT incidence and prevalence data were presented
as unadjusted rates and standardized for the age and sex
distribution of the EU27 population in 2010 [1]. Patient
survival on RRT and dialysis were based on incident RRT
patients. Patient and graft survival post-transplantation
only included patients receiving their ﬁrst renal transplant
between 2003 and 2007 or 2006 and 2010. The survival
analyses were based solely on data from renal registries
providing individual patient records. A detailed description
of the methods on patient and graft survival is given in
Appendix 1. More detailed data than those presented in
this current paper were published in the full 2012 ERA-
EDTA Registry Annual Report [2], which is also available
online at www.era-edta-reg.org.
The incidence of RRT for ESRD
In 2012, the total number of patients starting RRT for
ESRD among all the registries reporting to the ERA-EDTA
Registry was 69 035. These registries covered a total popu-
lation of 629.7 million, resulting in an unadjusted incidence
rate of 109.6 per million population (pmp). Figure 1A and
Figure 2 show the incidence of ESRD patients receiving RRT
per pmp on Day 1, among all national and regional renal
registries in 30 countries reporting to the ERA-EDTA Registry
in 2012. The highest unadjusted incidence rates were re-
ported in Portugal (219.9 pmp), Greece (209.7 pmp) and
Georgia (199.6 pmp), whereas the lowest unadjusted inci-
dence rates were reported in Montenegro (24.2 pmp),
Ukraine (27.6 pmp) and Russia (48.1 pmp). The incidence
rate standardized for the EU27 population was highest in
Israel (280.5 pmp), Georgia (227.5 pmp) and French-speaking
Belgium (201.1 pmp). The mean age at the start of RRT
across Europe was 62.0 years in the renal registries providing
individual level patient data and 58.2 years in the renal regis-
tries providing aggregated data (Figure 2). Figure 1B and
Figure 3 provide information on the incidence of RRT, per
million age-related population (pmarp), on Day 1 for older
patients. For the countries providing individual level data; the
incidence of RRT for patients aged 65–74 years or 75 years
and over varied considerably between the renal registries
(Figure 3). The lowest incidence rate of patients aged 65–74
and 75 years and over was reported in Finland (199.8 and
220.8 pmarp, respectively). A more than three times as high
incidence rate was reported in French-speaking Belgium
(619.4 pmarp) for patients aged 65–74 years and Dutch-
speaking Belgium (893.6 pmarp) for patients aged over 75
years (Figure 3). Within each country or region, there was a
wide variation in the proportion of ESRD patients aged 75
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Fig. 1. (A) The unadjusted incidence of ESRD patients on RRT, pmp on Day 1, among all national and regional renal registries in 30 countries reporting to the
ERA-EDTA Registry in 2012. The incidence data for Czech Republic and Slovakia include dialysis patients only. Dutch- and French-speaking Belgium, the Spanish
regions of Cantabria, Castile and León and Castile-La Mancha and the UK; England, Northern Ireland and Wales do not report on patients younger than 20
years. (B) The unadjusted incidence of ESRD patients aged 75 years and older on RRT, per million age-related population (pmarp) at Day 1, among all national
and regional renal registries in 17 countries providing individual level data to the ERA-EDTA Registry in 2012. B&H: Bosnia–Herzegovina; ME: Montenegro.
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years and over commencing RRT with the highest proportion
reported in Dutch-speaking Belgium (44%) and Greece (43%)
and the lowest proportion in Romania (15%) and Serbia
(15%). Within the countries supplying individual level data,
the four national or regional registries with the highest ad-
justed incidence of RRTon Day 1 (Greece, French- and Dutch-
speaking Belgium and France) also had the highest incidence
of RRT on Day 1 for patients 75 years and over (Figure 1A–B
and 3).
Table 1 presents the unadjusted incidence of RRT pmp
on Day 91, by treatment modality (haemodialysis, periton-
eal dialysis and transplantation) for the renal registries
providing individual and aggregated data. The incidence
rate of haemodialysis was highest in Portugal (184.7 pmp),
Greece (171.0 pmp) and Israel (153.7 pmp), whereas the in-
cidence rate of peritoneal dialysis was highest in the
Spanish regions of Asturias (38.2 pmp) and Galicia (32.9
pmp) and Sweden (32.6 pmp). The incidence rate of renal
transplants on Day 91 was highest in Norway (16.5 pmp),
the Netherlands (14.9 pmp) and Iceland (12.5 pmp).
Table 2 presents the percentage of patients by established
treatment modality (haemodialysis, peritoneal dialysis and
transplantation) on Day 91 after the start of RRT, by age
group. For patients 75 years and over, the vast majority
were treated with haemodialysis, and almost no patients
had a kidney transplant. Notably, within this age group the
Scandinavian countries (Norway, Sweden, Finland and
Denmark) had the highest percentage (about a quarter) of
patients treated with peritoneal dialysis.
For children (aged 0–19 years), we performed a separate
analysis of the incidence rate by age group and initial
treatment modality from a selected number of renal regis-
tries which are presented in Table 3. A more detailed over-
view of the paediatric RRT data in Europe can be found at
www.espn-reg.org.
The prevalence of RRT for ESRD
On the 31 December 2012, a total of 451 270 patients
with ESRD were receiving RRT among the renal registries
Fig. 2. Incidence of RRT, pmp at Day 1 in 2012, unadjusted (black bars) and standardized to the age and gender distribution of the EU27 population in
2010 (grey bars) and the mean and median age (years) at the start of RRT. Data are from renal registries providing individual level patient data (left panel)
and from renal registries providing aggregated data (right panel). The incidence data for the Czech Republic and Slovakia only include dialysis patients.
The mean and median age for Slovakia is based on dialysis patients and for Turkey only on haemodialysis patients. Dutch- and French-speaking Belgium,
the Spanish regions of Cantabria, Castile and León and Castile-La Mancha and the UK; England, Northern Ireland and Wales do not report on patients
younger than 20 years.
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reporting to the ERA-EDTA Registry, corresponding to an
unadjusted prevalence of 716.7 pmp. There was a sub-
stantial difference in the prevalence pmp throughout
Europe, both in the unadjusted prevalence and the preva-
lence standardized for the age and sex distribution of the
EU27 population (Figure 4). The unadjusted prevalence
was highest in Portugal (1670.2 pmp), French- and Dutch-
speaking Belgium (1251.3 and 1206.2 pmp, respectively),
whereas the unadjusted prevalence was lowest in Ukraine
(146.7 pmp), Russia (213.9 pmp) and Montenegro (309.7
pmp). The prevalence pmp standardized to the EU27 was
highest in French-speaking Belgium (1324.1 pmp) and the
Spanish regions of Murcia (1303.1 pmp) and Catalonia
(1221.3 pmp). In 2012, the mean age of the prevalent RRT
patients was 60.3 years within the renal registries provid-
ing individual level patient data and 56.6 years within the
Fig. 3. Incidence of ESRD patients on RRT, pmarp, unadjusted at Day 1, in 2012 for patients aged 65–74 years (black bars) and 75 years and over (grey
bars), and with the percentage of patients by the age group.
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renal registries providing aggregated data, with consider-
able variation across renal registries (Figure 4).
The unadjusted prevalence of patients aged 65–74
years and 75 years and over was 2400.2 and 2388.9
pmarp, respectively, within the renal registries providing
individual level patient data (Figure 5). Prevalent patients
aged 65–74 years formed 22% of the total prevalent
patient population from these registries and patients aged
75 years and over formed 20%. The prevalence pmarp for
patients aged 65–74 years was highest in French-speaking
Belgium (3654.2 pmarp) and the Spanish regions of
Murcia (3501.5 pmarp) and Catalonia (3382.4 pmarp). The
prevalence pmarp for patients aged 75 years and above
was highest in French- and Dutch-speaking Belgium
(4262.6 and 4093.8 pmarp, respectively) and the Spanish
region of Murcia (3701.5 pmarp).
Table 4 presents the unadjusted prevalence of ESRD pa-
tients receiving RRTpmp on 31st December 2012, by treat-
ment modality (haemodialysis, peritoneal dialysis and
transplantation) for the renal registries providing individ-
ual and aggregated data. The prevalence of haemodialysis
was highest in Portugal (997.6 pmp), Greece (844.4 pmp)
and Israel (691.0 pmp), whereas the prevalence of peri-
toneal dialysis was highest in the Spanish regions of
Galicia (97.6 pmp), Asturias (96.8 pmp) and Basque
country (92.6 pmp). The prevalence of patients living with
a functioning renal transplant was highest in the Spanish
regions of Basque country (670.8 pmp) and Catalonia
Table 1. Incident counts and rates, pmp of RRTat Day 91 (unadjusted) in 2012 by established therapy for countries/regions providing individual patient
data and for countries/regions providing aggregated data
Region
All All HD PD Tx Unknown/missing
N pmp pmp pmp pmp pmp
Country/region providing individual patient data, pmp
Austria 1054 124.8 104.1 15.0 5.7 0
Belgium
Dutch-speakinga 1089 171.1 150.0 16.8 4.2 0
French-speakinga 800 170.2 147.4 17.9 4.0 0.9
Bosnia and Herzegovina 407 116.0 112.3 3.4 0 0.3
Croatiab 595 139.4 123.4 13.7 2.0 0.2
Denmark 654 115.8 75.6 31.9 8.3 0
Finland 433 80.0 57.8 21.6 0.6 0
France 9305 142.2 117.0 14.9 6.2 4.0
Greece 2059 185.6 171.0 13.3 1.3 0
Iceland 19 59.2 28.1 18.7 12.5 0
Norway 499 99.4 63.4 19.5 16.5 0
Romania 2518 130.8 122.0 7.4 1.4 0
Serbia 837 116.3 102.2 12.4 1.7 0
Slovenia 240 116.7 110.8 5.3 0.5 0
Spain
Andalusia 947 112.9 89.3 17.9 5.7 0
Aragon 171 127.5 105.1 17.9 4.5 0
Asturias 131 121.9 81.0 38.2 2.8 0
Basque country 251 115.1 84.4 24.3 6.4 0
Cantabriaa 55 93.0 67.7 20.3 5.1 0
Castile and Leóna 287 113.5 87.4 22.9 3.2 0
Castile-La Manchaa 198 94.3 76.2 17.1 1.0 0
Cataloniab 854 112.8 82.3 19.0 11.5 0
Community of Madrid 659 102.6 82.1 14.5 6.1 0
Extremadura 127 114.6 96.6 17.1 0.9 0
Galicia 365 131.9 94.3 32.9 4.7 0
Region of Murciab 159 107.6 93.1 12.4 2.0 0
Valencian Region 711 138.6 109.8 24.6 4.3 0
Sweden 969 101.8 60.8 32.6 8.4 0
The Netherlands 1892 112.9 79.6 18.5 14.9 0
UK
All countriesa,b 6372 100.0 71.0 20.0 9.0 0
Englanda,b 5371 100.4 70.6 20.7 9.1 0
Northern Irelanda,b 168 92.3 65.8 15.0 11.5 0
Scotland 508 95.6 74.5 13.7 7.3 0
Walesa,b 332 108.0 75.4 23.2 9.4 0
Country/region providing aggregated patient data
Albania 177 63.3 57.9 4.6 0.7 0
Czech Republicc 1396 134.1 126.0 8.1 0
Estonia 105 79.4 61.2 16.6 1.5 0
Georgia 475 166.3 143.2 21.0 1.1 1.1
Israel 1356 171.4 153.7 12.3 5.4 0
Latvia 138 80.2 64.5 15.7 0.0 0
Montenegro 13 21.0 21.0 0.0 0.0 0
Portugald 2190 207.3 184.7 20.8 1.8 0
Slovakiac 772 142.7 136.8 5.9 0
HD, haemodialysis; PD, peritoneal dialysis; TX, transplant; pmp, per million population.
aPatients younger than 20 years of age are not reported.
bThe incident counts at Day 91 are estimated.
cData include dialysis patients only.
dOnly pre-emptive transplantations (at Day 1) are included. When cells are left empty, the data are unavailable.
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Table 2. Percentages of established RRTmodality at Day 91 (unadjusted) by age group for the countries/regions providing individual patient data
Region
All 0–19 20–44 45–64 65–74 ≥75
HD
(%)
PD
(%)
TX
(%)
Oth
(%)
HD
(%)
PD
(%)
TX
(%)
Oth
(%)
HD
(%)
PD
(%)
TX
(%)
Oth
(%)
HD
(%)
PD
(%)
TX
(%)
Oth
(%)
HD
(%)
PD
(%)
TX
(%)
Oth
(%)
HD
(%)
PD
(%)
TX
(%)
Oth
(%)
Austria 75 12 5 8 39 17 44 0 55 14 18 13 67 16 6 11 82 13 0 5 88 5 0 7
Belgium
Dutch-speakinga 59 10 3 29 38 26 11 26 57 15 4 24 61 10 3 26 63 4 0 33
French-speakinga 65 11 2 22 48 22 11 19 66 12 3 19 70 6 2 21 65 9 0 26
Bosnia and Herzegovina 94 3 0 3 75 25 0 0 88 7 0 5 93 2 0 5 96 2 0 3 98 2 0 0
Croatiab 88 10 1 1 13 50 38 0 81 10 6 3 85 14 0 0 92 7 0 1 95 5 1 0
Denmark 65 28 7 0 50 25 25 0 64 23 14 0 58 30 12 0 63 31 5 0 78 22 0 0
Finland 69 27 1 3 29 57 14 0 51 44 4 2 70 26 0 4 75 22 0 4 77 22 0 1
France 72 11 4 13 35 21 26 19 64 13 12 11 71 9 7 13 76 9 3 12 73 12 0 15
Greece 89 7 1 3 61 28 11 0 85 9 4 2 87 9 1 3 89 7 0 4 92 6 0 2
Iceland 47 32 21 0 0 0 0 0 0 0 0 0 44 22 33 0 67 0 33 0 43 57 0 0
Norway 64 20 17 0 20 20 60 0 62 17 22 0 56 20 24 0 68 16 16 0 73 24 3 0
Romania 93 6 1 0 68 32 0 0 89 6 5 0 93 6 0 0 94 6 0 0 96 4 0 1
Serbia 86 11 1 2 86 0 14 0 67 20 9 4 90 8 0 2 90 9 0 1 87 13 0 1
Slovenia 95 5 0 0 100 0 0 0 88 12 0 0 90 9 1 0 97 3 0 0 100 0 0 0
Spain
Andalusia 79 16 5 0 42 25 33 0 67 19 14 0 75 18 7 0 82 16 2 0 90 10 0 0
Aragon 81 14 4 2 0 0 100 0 58 21 21 0 77 23 0 0 81 15 0 4 93 5 0 2
Asturias 66 31 2 0 0 100 0 0 38 63 0 0 52 43 4 0 77 19 3 0 80 20 0 0
Basque country 73 21 6 0 0 0 100 0 54 26 20 0 65 31 5 0 82 17 2 0 88 12 0 0
Cantabriaa 73 22 5 0 43 14 43 0 64 36 0 0 93 7 0 0 83 17 0 0
Castile and Leóna 77 20 3 0 52 28 20 0 63 35 2 0 83 16 2 0 91 9 0 0
Castile-La Manchaa 81 18 1 0 56 38 6 0 75 24 1 0 75 25 0 0 98 2 0 0
Cataloniab 53 17 10 20 36 27 38 0 40 16 29 15 42 24 17 17 59 16 4 20 66 9 0 25
Extremadura 84 15 1 0 0 0 0 0 61 39 0 0 76 21 2 0 100 0 0 0 90 10 0 0
Galicia 72 25 4 0 67 33 0 0 43 46 11 0 55 38 7 0 85 15 0 0 87 13 0 0
Community of Madrid 80 14 6 0 57 14 29 0 55 31 13 0 73 20 7 0 87 9 4 0 93 5 2 0
Region of Murciab 87 12 2 0 50 50 0 0 60 30 11 0 92 8 0 0 93 7 0 0 94 6 0 0
Valencian Region 79 18 3 0 44 33 22 0 59 32 9 0 69 26 5 0 87 12 1 0 92 8 0 0
Sweden 60 32 8 0 7 41 52 0 51 30 19 0 57 34 9 0 59 37 5 0 74 25 1 0
The Netherlands 70 16 13 0 31 10 59 0 50 17 32 0 61 17 21 0 74 19 7 0 87 13 0 0
UK
All countriesa,b 69 20 9 2 51 26 21 2 63 23 12 2 75 18 5 2 83 14 0 3
Englanda,b 68 21 9 3 49 27 21 2 62 23 12 2 74 19 5 3 82 14 0 4
Northern Irelanda,b 70 16 12 1 43 22 36 0 65 18 17 0 69 26 3 3 95 4 0 1
Scotland 78 14 8 0 20 40 40 0 67 17 17 0 73 15 11 0 88 12 1 0 86 13 1 0
Walesa,b 70 21 9 0 52 29 19 0 60 29 11 0 70 21 9 0 91 9 0 0
HD, haemodialysis; PD, peritoneal dialysis; TX, transplant; oth, other (includes haemoﬁltration, haemodiaﬁltration and unknown).
Categories may not add up because of missing values or rounding off; percentages are row percentages. When cells are left empty (complete) data are unavailable.
aPatients younger than 20 years of age are not reported.
bThe incident counts at Day 91, on which the data presented in this table are based, are estimated (see annual report for methods).
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Table 3. Incident rates per million age-related population of RRTat Day 1 over the time period 2011–12 for patients aged 0–19 by age and treatment
modality
0–19 0–4 5–9 10–14 15–19
All HD PD Tx All HD PD Tx All HD PD Tx All HD PD Tx All HD PD Tx
pmarp pmarp pmarp pmarp pmarp
2011–12 7.6 3.8 2.0 1.7 7.2 2.2 4.2 0.7 3.7 1.2 0.8 1.5 6.9 3.1 1.3 2.3 12.6 8.5 1.6 2.2
HD, haemodialysis; PD, peritoneal dialysis; TX, transplant; pmarp, per million age-related population.
Data from France include a coverage of 99.37% in 2011 and 100% in 2012. The Spanish region of Murcia is only included in 2012.
Fig. 4: Prevalence of RRT, pmp on 31 December 2012, unadjusted (black bars) and standardized to the age and gender distribution of the EU27 population
(grey bars) and the mean and median age (years). Data are from the renal registries providing individual level patient data (left panel) and from renal
registries providing aggregated data (right panel). Data for Israel and Slovakia only include dialysis patients. Dutch- and French-speaking Belgium, the
Spanish regions of Cantabria, Castile and León and Castile-La Mancha and the UK; England, Northern Ireland and Wales do not report on patients younger
than 20 years.
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(659.1 pmp) and Norway (639.2 pmp). Table 5 presents
the percentage of patients by established treatment mo-
dality (haemodialysis, peritoneal dialysis and transplant-
ation) on 31st December 2012, by age group. For prevalent
patients 75 years and over, the percentage of patients re-
ceiving haemodialysis varied from 54% in Finland to 98% in
Slovenia. In this age group, the percentage of patients re-
ceiving peritoneal dialysis was highest in Denmark (16%)
and Sweden (15%), whereas Norway reported the highest
number of patients living with a functioning kidney allograft
(38%). These results were based only on countries with
<10%missing values for treatment modality.
The prevalence of children with ESRD by age group and
treatment modality is presented in Table 6. Overall on the
31 December 2012 the prevalence of children with ESRD
was 54.7 pmarp: the majority (41.5 pmarp) had a func-
tioning renal transplant whereas 8.1 pmarp were receiving
haemodialysis and 4.6 pmarp peritoneal dialysis.
Fig. 5. Prevalence of RRT, pmp on 31 December 2012 for patients with ESRD aged 65–74 years (black bars) and 75 years and over (grey bars), and with the
percentage of patients by the age group.
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Renal transplants in 2012
During 2012 there were a total of 15 673 renal transplants
performed within the countries and regions reporting to
the ERA-EDTA Registry, corresponding to a renal trans-
plantation rate of 28.3 pmp (Figure 6). Of these 12 252
were from a deceased donor source (22.1 pmp, 78%) and
3322 renal transplants were from a living donor source
(6.0 pmp, 21%). The kidney transplantation rate varied
considerably between the countries and regions reporting
to the ERA-EDTA Registry, with the highest rates pmp seen
in the Spanish regions of Catalonia and Cantabria (74.0
and 60.9 pmp, respectively) and in Northern Ireland (64.2
pmp). The proportion of living donor to deceased donor
transplants also varied considerably within each country
and region (Figure 6). Notably, for the countries with a
transplantation rate >20.0 pmp, Israel and the Nether-
lands were the only two countries with a higher proportion
of living to deceased donor renal transplants (1.54 and
1.03, respectively).
The mean age at renal transplantation (available from
the renal registries supplying individual level data and
Table 4. Prevalence of RRTon 31 December 2012, by established therapy as pmp (unadjusted) for individual and aggregated data
Region
All All
HD PD Tx Unknown/missing
N pmp pmp pmp pmp pmp
Country/region providing individual patient data
Austria 8635 1022.7 460.5 46.0 516.3 0
Belgium
Dutch-speakinga 7679 1206.2 641.0 57.3 507.8 0
French-speakinga 5883 1251.3 665.1 59.8 523.0 3.5
Bosnia and Herzegovina 2519 718.1 642.8 23.4 51.6 0.3
Croatia 4411 1033.2 606.5 42.9 383.9 0
Denmark 4927 872.3 367.5 90.5 410.7 3.5
Finland 4373 807.7 266.0 59.3 482.5 0
France 74 521 1138.7 580.3 41.9 507.4 9.2
Greece 12 598 1135.7 844.4 59.9 231.3 0
Iceland 219 682.8 177.7 65.5 439.6 0
Norway 4453 887.3 208.8 39.3 639.2 0
Romaniab 14 747 765.9 628.9 78.9 57.9 0.2
Serbia 5414 752.0 586.9 58.6 106.4 0.1
Slovenia 2048 995.5 662.6 22.8 310.1 0
Spain
Andalusia 8905 1062.0 478.0 46.6 537.2 0.1
Aragon 1452 1082.7 424.3 46.2 612.2 0
Asturias 1152 1072.3 382.6 96.8 592.9 0
Basque country 2488 1140.8 377.4 92.6 670.8 0
Cantabriaa 575 972.6 340.0 66.0 566.6 0
Castile and Leóna 2689 1063.6 432.3 69.2 552.2 9.9
Castile-La Manchaa 2114 1006.6 397.1 57.1 547.1 5.2
Catalonia 9086 1200.1 492.4 48.6 659.1 0
Community of Madrid 6338 987.2 379.6 54.7 552.9 0
Extremadura 1163 1049.5 475.6 66.8 465.6 41.5
Galicia 3271 1182.2 526.6 97.6 558.0 0
Region of Murcia 1703 1155.0 619.2 48.8 486.3 0.7
Valencian Region 6111 1191.4 647.7 64.9 478.4 0.4
Sweden 8882 933.0 320.2 82.9 530.0 0
The Netherlands 15 472 923.4 325.8 58.4 539.1 0.1
United Kingdom
All countriesa 55 238 867.1 372.0 60.4 434.6 0.1
Englanda 46 456 868.4 373.3 62.1 433.0 0.1
Northern Irelanda 1557 853.8 391.0 47.2 415.7 0
Scotland 4557 857.6 362.1 45.7 449.8 0
Walesa 2743 892.3 358.8 67.3 465.8 0.3
Country/ region providing aggregated patient data
Albania 909 325.1 234.6 17.9 72.6 0
Czech Republic 10 371 996.2 554.4 47.0 394.8 0
Estonia 733 554.0 194.3 31.7 328.0 0
Georgia 1559 545.8 479.0 14.7 48.7 3.5
Israelc 5795 732.6 691.0 41.6 0
Latvia 926 538.2 195.3 52.9 290.0 0
Montenegro 192 309.7 164.5 9.7 135.5 0
Poland 28 226 747.5 463.9 29.4 254.2 0
Portugal 17 641 1670.2 997.6 70.3 602.3 0
Russia 30 349 213.9 156.8 13.2 43.9 0
Slovakiac 3220 595.1 577.5 17.6 0
Spain (18 of 19 regions) 50 909 1092.1 478.3 59.2 554.6 0
Turkey 815.6
Ukraine 6669 146.7 109.0 19.3 18.5 0
HD, haemodialysis; PD, peritoneal dialysis; TX, transplant; pmp, per million population.
aPatients younger than 20 years of age are not reported.
bThe overall prevalence of RRT is underestimated by ∼3% due to an estimated 30% underreporting of patients living with a functioning graft.
cData include dialysis patients only. When cells are left empty, the data are unavailable.
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Table 5. Percentages of established RRTmodality (unadjusted) of prevalent patients on 31 December 2012, by age group for the countries/regions providing individual patient data
Region
All 0–19 20–44 45–64 65–74 ≥75
HD
(%)
PD
(%)
TX
(%)
Oth
(%)
HD
(%)
PD
(%)
TX
(%)
Oth
(%)
HD
(%)
PD
(%)
TX
(%)
Oth
(%)
HD
(%)
PD
(%)
TX
(%)
Oth
(%)
HD
(%)
PD
(%)
TX
(%)
Oth
(%)
HD
(%)
PD
(%)
TX
(%)
Oth
(%)
Austria 34 4 50 11 9 7 79 5 21 4 65 10 24 5 60 11 39 5 46 11 64 4 19 14
Belgium
Dutch-speakinga 32 5 42 21 18 8 64 10 19 5 63 13 31 5 44 20 52 3 11 34
French-speakinga 41 5 42 13 23 6 62 9 30 4 57 9 39 5 41 15 64 5 13 18
Bosnia and Herzegovina 81 3 7 9 65 8 27 0 60 6 20 13 79 3 7 11 91 2 1 5 95 1 0 3
Croatia 58 4 37 1 4 27 69 0 28 6 66 1 46 4 49 1 72 3 23 2 93 3 3 1
Denmark 42 10 47 0 11 7 82 0 25 5 69 1 33 9 58 0 51 14 34 1 78 16 6 0
Finland 26 7 60 7 3 7 90 1 16 8 71 5 19 7 68 6 31 7 53 9 54 9 27 10
France 41 4 45 10 11 5 79 6 26 2 67 5 32 2 58 8 44 4 41 11 66 7 10 18
Greece 58 5 20 16 31 21 45 3 32 5 45 18 44 5 30 20 66 5 13 16 84 5 1 10
Iceland 26 10 64 0 0 20 80 0 10 4 87 0 23 2 75 0 29 7 64 0 58 36 6 0
Norway 24 4 72 0 5 2 93 0 14 2 84 0 16 3 80 0 27 4 69 0 50 12 38 0
Romaniab 82 10 8 0 53 28 19 0 69 9 21 1 83 9 7 0 88 11 1 0 87 13 0 0
Serbia 66 8 14 12 32 13 48 6 40 6 39 15 66 7 12 14 80 10 1 8 83 9 0 8
Slovenia 67 2 31 0 29 14 57 0 40 4 56 0 56 3 41 0 74 2 24 0 98 1 1 0
Spain
Andalusia 45 4 51 0 9 3 88 0 27 4 69 0 33 4 63 0 52 4 44 0 83 5 12 0
Aragon 39 4 57 0 13 0 88 0 19 8 73 0 27 3 69 0 42 6 51 0 68 2 29 0
Asturias 35 9 55 0 13 25 63 0 21 11 67 0 23 10 67 0 35 6 59 0 64 9 27 0
Basque country 33 8 59 0 3 6 90 0 21 7 72 0 22 10 68 0 34 7 59 0 65 7 28 0
Cantabriaa 35 7 58 25 2 73 0 22 8 70 0 36 6 58 0 71 10 19 0
Castile and Leóna 41 7 52 1 23 5 71 1 25 6 69 0 38 7 54 0 72 8 18 2
Castile-La Manchaa 39 6 54 1 17 10 73 0 30 6 64 0 40 5 55 1 71 3 26 1
Catalonia 25 4 55 16 6 5 88 2 13 3 76 8 17 4 66 12 25 5 53 17 48 3 22 27
Extremadura 45 6 44 4 0 0 100 0 28 10 56 6 30 7 57 5 52 4 40 4 84 4 12 0
Galicia 45 8 47 0 11 28 61 0 24 8 68 0 31 10 60 0 49 6 45 0 81 8 12 0
Community of Madrid 38 6 56 0 11 8 81 0 20 8 72 0 27 6 66 0 41 5 54 0 71 3 26 0
Region of Murcia 54 4 42 0 10 20 70 0 33 7 61 0 36 4 60 0 62 4 34 0 92 3 6 0
Valencian Region 54 5 40 0 17 11 72 0 33 7 61 0 41 6 52 0 56 5 39 0 88 4 8 0
Sweden 34 9 57 0 8 9 83 0 20 5 75 0 25 7 68 0 38 11 52 0 69 15 15 0
The Netherlands 35 6 58 0 6 5 89 0 20 4 77 0 24 6 70 0 38 7 54 0 74 9 17 0
UK
All countriesa 41 7 50 2 24 5 69 1 32 6 60 2 50 9 39 2 76 9 12 3
Englanda 41 7 50 2 24 5 69 1 32 6 60 2 50 9 39 3 75 10 11 4
Northern Irelanda 44 6 49 2 22 7 70 1 33 4 61 2 60 7 30 3 78 7 12 3
Scotland 42 5 52 0 8 15 77 0 27 3 70 0 34 5 61 0 56 8 36 0 80 7 14 0
Walesa 40 8 52 0 22 6 73 0 30 6 64 0 48 10 42 0 77 10 13 0
HD, haemodialysis; PD, peritoneal dialysis; TX, transplant; oth, other (includes haemoﬁltration, haemodiaﬁltration and unknown).
Categories may not add up because of missing values or rounding off; percentages are row percentages. When cells are left empty (complete) data are unavailable.
aPatients younger than 20 years of age are not reported.
bThe overall prevalence of RRT is underestimated by ∼3% due to an estimated 30% underreporting of patients living with a functioning graft.
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limited to adult patients) was 51.9 years (Figure 6). The
mean recipient age at the time of renal transplantation
was greatest in the Spanish regions of Aragon (57.0 years)
and Asturias (55.7 years) and Norway (55.1 years). The
youngest mean recipient ages at the point of renal trans-
plantation were reported by Romania (38.7 years), Bosnia
Table 6. Prevalent rates per million age-related population of RRTon 31 December in 2012 for patients aged 0–19 by age and treatment modality
0–19 0–4 5–9 10–14 15–19
All HD PD Tx All HD PD Tx All HD PD Tx All HD PD Tx All HD PD Tx
pmarp pmarp pmarp pmarp pmarp
2012 54.7 8.1 4.6 41.5 19.4 3.9 7.3 8.1 35.9 3.5 2.9 29.3 58.4 5.9 3.4 48.8 104.0 19.0 4.8 79.1
HD, haemodialysis; PD, peritoneal dialysis; TX, transplant; pmarp, per million age-related population.
Fig. 6. Renal transplants performed, pmp in 2012, unadjusted, with mean and median age at transplantation. Data are from renal registries providing
individual patient level data and aggregated data. For the registries providing individual patient data, the percentage of patients aged over 65 years and
percentage of patients aged over 75 years at the point of transplantation are presented. For some countries transplantation data were obtained from
alternate sources: UK: NHS Blood and Transplant, Slovakia: Slovak Centre of Organ Transplantation, Spain (18 of 19 regions): Organización Nacional de
Transplantes. For Romania the transplantation activity reﬂects 70% of the total transplantation activity in the country, due to an underreporting of pre-
emptive transplantations. The mean/median age and percentage over 65 or over 75 years is limited to the adult patient cohort only.
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and Herzegovina (39.5 years) and Serbia (40.7 years). The
proportion of patients aged 65 years and over at the time
of renal transplantation also varied across the registries
from 35% in the Spanish region of Aragon to 0% in Iceland,
Slovenia and Bosnia and Herzegovina.
Patient and graft survival
Survival analyses included data from 22 registries in 11
countries which provided individual patient data for the
period of 2003–2010. The 1-, 2- and 5-year adjusted sur-
vival probabilities for patients with ESRD commencing RRT
between 2003 and 2007 are presented for the total cohort
and for the older age groups in Table 7. Adjustments were
made for age, gender and the distribution of primary renal
disease (see Appendix 1). Five-year survival for all RRT pa-
tients was 59.7% (95% conﬁdence interval, CI: 59.3–60.0)
which fell to 39.3% (95% CI: 38.7–39.9) in patients 65–74
years and 21.3% (95% CI: 20.8–21.9) in patients over 75
years.
Afﬁliated registries
Albania: N. Thereska, A. Strakosha and N. Pasko; Austria:
R. Kramar; Belgium, Dutch-speaking: H. Augustijn, B. De Moor
and J. De Meester; Belgium, French-speaking: J.M. des
Grottes and F. Collart; Bosnia–Herzegovina: H. Resić,
B. Prnjavorac and L. Lukić; Croatia: S. Čala; Czech Republic:
I. Rychlík, J. Potucek and F. Lopot; Denmark: J.G. Heaf;
Estonia: M. Rosenberg, M. Luman and Ü. Pechter; Finland:
P. Finne and C. Grönhagen-Riska; France: M. Lassalle and
C. Couchoud; Georgia: N. Kantaria and Dialysis Nephrology
and Transplantation Union of Georgia; Greece: G.A. Ioanni-
dis; Iceland: R. Palsson; Israel: R. Dichtiar, T. Shohat and
E. Golan; Latvia: H. Cernevskis and V. Kuzema; Monten-
egro: M. Ratkovic, D Radunovic and S. Ivanovic; Norway:
T. Leivestad; Poland: B. Rutkowski, G. Korejwo and
P. Jagodziński; Portugal: F. Macário, F. Nolasco and R. Filipe;
Romania: G. Mircescu, L. Garneata and E. Podgoreanu;
Russia: N.A. Tomilina and B.T. Bikbov; Serbia: Working group
of Serbian RRT Registry and all of the Serbian renal units;
Slovakia: V. Spustová, I. Lajdova and M. Karolyova; Slovenia:
J. Buturovic-Ponikvar, J. Gubenšek and M. Arnol; Spain,
Andalusia: P. Castro de la Nuez; Spain, Aragon: J.I. Sanchez
Miret and J.M. Abad Diez; Spain, Asturias: R. Alonso de la
Torre, J.R. Quirós and RERCA working Group; Spain, Basque
country: Á. Magaz, J. Aranzabal, M. Rodrigo and I. Moina;
Spain, Cantabria: M. Arias Rodríquez and O García Ruiz;
Spain, Castile and León: R. González and C. Fernández-
Renedo; Spain, Castile-La Mancha: G. Gutiérrez Ávila and
I. Moreno Alía; Spain, Catalonia: E. Arcos, J. Comas and
J. Tort; Spain, Extremadura: J.M. Ramos Aceitero and M.A.
García Bazaga; Spain, Galicia: E. Bouzas-Caamaño and
J. Sánchez-Ibáñez; Spain, Community of Madrid: M. Aparicio
de Madre and C. Chamorro Jambrina; Spain, Region of
Murcia: C. Santiuste de Pablos and I. Marín Sánchez; Spain,
Valencian region: O. Zurriaga Llorens and M. Ferrer Alamar;
Spain: Spanish RRT National Registry at ONT, Spanish Re-
gional Registries and Spanish Society of Nephrology (SEN);
Sweden: K.G. Prütz, L. Bäckman, M. Evans, S. Schön,
M. Stendahl and B. Rippe; the Netherlands: A. Hoitsma
and A. Hemke; Turkey: G. Süleymanlar, M.R. Maltiparmak
and N. Seyahi; Ukraine: M. Kolesnyk, M. Kulyzkyi and
S. Nikolaenko; UK, England/Northern Ireland/Wales: all the
staff of the UK Renal Registry and of the renal units sub-
mitting data; UK, Scotland: all of the Scottish renal units.
ERA-EDTA Registry committee members
R. Vanholder, Belgium (ERA-EDTA President); C. Wanner,
Germany (Chairman); F.J. Caskey, UK; F. Collart, Belgium;
C. Couchoud, France; D. Fouque, France; J.W. Groothoff,
the Netherlands; J.G. Heaf, Denmark; P. Ravani, Italy;
Table 7. One, two and ﬁve-year patient and graft survival probabilities (95% Conﬁdence interval), for all patients and for patients above 65 years of age,
adjusted for age, gender and primary diagnosis
2006–10 cohort 2003–07 cohort
1 year 2 year 1 year 2 year 5 year
Incident RRTpatients
All patients 89.7 (89.5–89.8) 82.2 (82.0–82.5) 88.7 (88.5–88.9) 80.6 (80.3–80.9) 59.7 (59.3–60.0)
65–74 82.3 (81.8–82.8) 70.5 (70.0–71.1) 80.3 (79.8–80.7) 67.6 (67.1–68.2) 39.3 (38.7–39.9)
75+ 72.6 (72.1–73.2) 56.7 (56.1–57.3) 70.4 (69.8–70.9) 53.2 (52.6–53.8) 21.3 (20.8–21.9)
Patient survival on dialysis
All patients 88.3 (88.1–88.5) 79.7 (79.4–80.0) 86.9 (86.7–87.1) 77.5 (77.2–77.8) 52.5 (52.0–52.9)
65–74 81.9 (81.5–82.4) 69.7 (69.1–70.2) 79.9 (79.4–80.4) 66.9 (66.3–67.4) 36.7 (36.1–37.3)
75+ 72.4 (71.9–73.0) 56.4 (55.8–57.0) 70.1 (69.5–70.7) 52.9 (52.2–53.5) 20.9 (20.4–21.5)
Patient survival after ﬁrst renal transplantation (deceased donor)
All patients 97.4 (97.1–97.6) 96.1 (95.8–96.4) 97.2 (97.0–97.4) 96.0 (95.7–96.2) 91.5 (91.0–91.9)
65+ 91.6 (90.4–92.8) 87.8 (86.4–89.2) 89.7 (88.3–91.1) 85.6 (84.0–87.3) 72.6 (70.5–74.8)
Patient survival after ﬁrst renal transplantation (living donor)
All patients 98.9 (98.7–99.2) 98.3 (98.0–98.6) 98.5 (98.1–98.8) 97.6 (97.1–98.0) 95.1 (94.4–95.8)
65+ 95.4 (93.5–97.3) 92.9 (90.5–95.3) 95.4 (92.8–98.1) 92.9 (89.7–96.3) 84.3 (79.7–89.3)
Graft survival after ﬁrst renal transplantation (deceased donor)
All patients 91.7 (91.3–92.2) 89.3 (88.8–89.7) 91.0 (90.6–91.4) 88.3 (87.9–88.8) 79.9 (79.2–80.5)
65+ 85.8 (84.2–87.3) 81.5 (79.8–83.2) 82.7 (80.9–84.6) 78.4 (76.4–80.4) 64.1 (61.8–66.5)
Graft survival after ﬁrst renal transplantation (living donor)
All patients 95.7 (95.2–96.2) 93.8 (93.2–94.5) 95.0 (94.4–95.7) 93.1 (92.3–93.8) 86.8 (85.8–87.8)
65+ 93.0 (90.6–95.4) 90.2 (87.4–93.1) 92.5 (89.1–96.0) 89.4 (85.4–93.5) 81.3 (76.2–86.6)
Based on data from Austria, Dutch- and French-speaking Belgium, Denmark, Finland, Greece, Iceland, Norway, the Spanish renal registries of Andalusia,
Aragon, Asturias, Basque country, Cantabria, Castile and León, Catalonia, Extremadura and Valencian region, Sweden, the Netherlands and the UK (all
countries). Methods are described in Appendix 1.
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I. Rychlik, Czech Republic; F. Schaefer, Germany and
S. Schön, Sweden.
ERA-EDTA Registry ofﬁce staff
K.J. Jager (Managing Director), R. Cornet, F.W. Dekker,
G. Guggenheim, A. Kramer, M. Noordzij, M. Pippias, V.S.
Stel, K.J. van Stralen and A.J. Weerstra.
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Appendix 1
Coverage of European population by the ERA-EDTA
Registry
European countries supplying data to the ERA-EDTA Regis-
try in 2012: Albania, Austria, Belgium, Bosnia and Herze-
govina, Croatia, Czech Republic, Denmark, Estonia, Finland,
France, Georgia, Greece, Iceland, Latvia, Montenegro, the
Netherlands, Norway, Poland, Portugal, Romania, Russia,
Serbia, Slovakia, Slovenia, Spain, Sweden, Turkey, Ukraine
and the UK.
European countries without renal registries able to supply
data to the ERA-EDTA Registry in 2012: Andorra, Armenia,
Azerbaijan, Belarus, Bulgaria, Cyprus, Former Yugoslav Re-
public of Macedonia, Germany, Hungary, Ireland, Italy,
Kosovo (under United Nations Security Council Resolution
1244/99), Liechtenstein, Lithuania, Luxembourg, Malta,
Moldova, Monaco, San Marino and Switzerland.
The total coverage of the European population by the
ERA-EDTA Registry in 2012 was 71.3%. For this calculation
only the proportion of the population residing in the
European part of Russia and Turkey were considered.
Statistical methods
Patient and graft survival
The survival probabilities of all incident ESRD patients re-
ceiving RRT, dialysis patients and of patients receiving a
ﬁrst renal transplant between 2003 and 2007 or between
2006 and 2010 are presented in Table 7. The Cox regres-
sion model was used for the adjusted survival analyses for
both the total group and the older subgroup of patients
(65–74 and 75 years and over). The patients were followed
until 31st December 2012.
For the analysis of patient survival on RRT, the ﬁrst day
of RRT was taken as the starting point and the event
studied was death. Censored observations were recovery
of renal function, loss to follow-up and end of follow-up
time. Adjustments were made for ﬁxed values for age
(60 years), gender (60% men) and primary renal disease
(20% diabetes mellitus, 17% hypertension/renal vascular
disease, 15% glomerulonephritis and 48% other cause).
In all the analyses of the older subgroups the correspond-
ing ﬁxed values were used with the exception of age.
For the analysis of patient survival on dialysis the ﬁrst
day on dialysis was taken as the starting point, the event
studied was death and censored observations were recov-
ery of renal function, loss to follow-up, end of follow-up
time and renal transplantation. Adjustments were made
for ﬁxed values of age (60 years), gender (60% men) and
primary renal disease (20% diabetes mellitus, 17% hyper-
tension/renal vascular disease, 15% glomerulonephritis
and 48% other cause).
For the analysis of patient and graft survival after trans-
plantation, the date of the ﬁrst renal transplantation was
deﬁned as the ﬁrst day of follow-up. The event studied for
the patient survival after transplantation was death, while
for the graft survival the events were graft failure and
death. Censored observations were loss to follow-up and
end of the follow-up time. Adjustments were made for
ﬁxed values of age (45 years), gender (60% men) and
primary renal disease (10% diabetes mellitus, 8% hyper-
tension/renal vascular disease, 28% glomerulonephritis
and 54% other cause).
Patients for whom age, gender or primary renal disease
was missing were excluded from the analysis.
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